Effect of Baseline HIV Disease Parameters on CD4+ T Cell Recovery After Antiretroviral Therapy Initiation in Kenyan Women
暂无分享,去创建一个
R. Kaul | N. Nagelkerke | L. McKinnon | M. Kimani | C. Wachihi | F. Muriuki | Anthony Kariri | R. Lester | L. Gelmon | T. Ball | F. Plummer | J. Kimani
[1] M Egger,et al. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. , 1999, JAMA.
[2] M. Lindegren,et al. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[3] R. Dersimonian,et al. Incomplete CD4 T cell recovery in HIV-1 infection after 12 months of highly active antiretroviral therapy is associated with ongoing increased CD4 T cell activation and turnover. , 2003, Journal of acquired immune deficiency syndromes.
[4] Jeffrey N. Martin,et al. T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. , 2003, The Journal of infectious diseases.
[5] J. Benito,et al. Differential Upregulation of CD38 on Different T-Cell Subsets May Influence the Ability to Reconstitute CD4+ T Cells Under Successful Highly Active Antiretroviral Therapy , 2005, Journal of acquired immune deficiency syndromes.
[6] A. Flahault,et al. Mechanisms involved in the low-level regeneration of CD4+ cells in HIV-1-infected patients receiving highly active antiretroviral therapy who have prolonged undetectable plasma viral loads. , 2005, The Journal of infectious diseases.
[7] D. Podzamczer,et al. Discontinuation of primary and secondary Toxoplasma gondii prophylaxis is safe in HIV-infected patients after immunological restoration with highly active antiretroviral therapy: results of an open, randomized, multicenter clinical trial. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[8] R. Cheynier,et al. Naïve T-Cell Depletion Related to Infection by X4 Human Immunodeficiency Virus Type 1 in Poor Immunological Responders to Highly Active Antiretroviral Therapy , 2006, Journal of Virology.
[9] S. Kalams,et al. Low CD4+ T cell nadir is an independent predictor of lower HIV-specific immune responses in chronically HIV-1-infected subjects receiving highly active antiretroviral therapy. , 2006, The Journal of infectious diseases.
[10] R. Haubrich,et al. Determinants of CD4+ T cell recovery during suppressive antiretroviral therapy: association of immune activation, T cell maturation markers, and cellular HIV-1 DNA. , 2006, The Journal of infectious diseases.
[11] Anne M Johnson,et al. Changes in the risk of death after HIV seroconversion compared with mortality in the general population. , 2008, JAMA.
[12] M. Muñoz-Fernández,et al. Negative influence of age on CD4+ cell recovery after highly active antiretroviral therapy in naive HIV-1-infected patients with severe immunodeficiency. , 2008, The Journal of infection.
[13] A. Fauci,et al. Universal voluntary testing and treatment for prevention of HIV transmission. , 2009, JAMA.
[14] Giulia Marchetti,et al. The absence of CD4+ T cell count recovery despite receipt of virologically suppressive highly active antiretroviral therapy: clinical risk, immunological gaps, and therapeutic options. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[15] M. Lederman,et al. Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. , 2009, The Journal of infectious diseases.
[16] Stephen R Cole,et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies , 2009, The Lancet.
[17] R. Shafer,et al. Incomplete reconstitution of T cell subsets on combination antiretroviral therapy in the AIDS Clinical Trials Group protocol 384. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[18] Michael J Silverberg,et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. , 2009, The New England journal of medicine.
[19] B. Agan,et al. CD4 T cell count reconstitution in HIV controllers after highly active antiretroviral therapy. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.